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Abstract: The bile salt export pump (BSEP) is the primary canalicular transporter responsible for
the secretion of bile acids from hepatocytes into bile canaliculi, and inhibition of this transporter has
been associated with drug-induced liver injury (DILI). A common variant (rs2287622; p.V444A) in the
gene encoding BSEP has been associated with an increased risk of cholestatic DILI. Although p.444V
BSEP (reference) and p.444A BSEP (variant) do not differ in their transport kinetics of taurocholic acid
(TCA), transport of the more abundant glycocholic acid (GCA) has not been investigated. Importantly,
differences in the susceptibility of p.444V and p.444A BSEP to inhibition by drugs causing cholestatic
DILI have not been investigated. To address these issues, the transport kinetics of GCA were evaluated
by incubating membrane vesicles expressing either p.444V or p.444A BSEP with GCA over a range of
concentrations (1, 10, 25, 50, and 100 ฀M). The abilities of commonly used cholestatic medications to
inhibit the transport of TCA and GCA by the reference and variant proteins were compared. Resulting
data indicated that GCA transport kinetics for reference and variant BSEP followed Michaelis-Menten
kinetics and were not statistically different [ Vmax values of 1132 ± 246 and 959 ± 256 pmol min-1 (mg
of protein)-1, respectively, and Km values of 32.7 ± 18.2 and 45.7 ± 25.5 ฀M, respectively]. There were
no statistically significant differences between the reference and variant BSEP in the inhibition of TCA
or GCA transport by the cholestatic drugs tested. In conclusion, differential inhibition of TCA or GCA
transport cannot account for an association between the variant BSEP and the risk for cholestatic DILI
due to the drugs tested.
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Abstract 
The bile salt export pump (BSEP) is the primary canalicular transporter responsible for the 
secretion of bile acids from hepatocytes into bile canaliculi, and inhibition of this transporter has 
been associated with drug-induced liver injury (DILI). A common variant (rs2287622; p.V444A) 
in the gene encoding for BSEP has been associated with increased risk of cholestatic DILI. 
Although 444V BSEP (reference) and 444A BSEP (variant) do not differ in the transport kinetics 
of TCA, transport of the more abundant GCA has not been investigated. Importantly, differences 
in susceptibility of 444V and 444A BSEP to inhibition by drugs causing cholestatic DILI has not 
been investigated. To address these issues, the transport kinetics of GCA were evaluated by 
incubating membrane vesicles expressing either 444V or 444A BSEP with GCA over a range of 
concentrations (1, 10, 25, 50, 100 µM). The ability of commonly used cholestatic medications to 
inhibit transport of TCA and GCA by the reference and variant proteins were compared.  Resulting 
data indicated that GCA transport kinetics for reference and variant BSEP followed Michaelis-
Menten kinetics and were not statistically different (Vmax: 1132 ± 246 vs. 959 ± 256 pmol/min/mg 
protein, respectively; Km: 32.7 ± 18.2 vs. 45.7 ± 25.5 µM, respectively). There were no statistically 
significant differences between the reference and variant BSEP in the inhibition of TCA or GCA 
transport by the cholestatic drugs tested. In conclusion, an association between the variant BSEP 
and risk for cholestatic DILI due to the drugs tested cannot be accounted for by differential 
inhibition of TCA or GCA transport. 
Keywords: transporters, cholestasis, bile salt export pump, drug-induced liver injury 
Introduction  
Transporters play an essential role in the disposition of both medications and endogenous 
substrates, including bile acids. Bile acids are key metabolic regulators that are synthesized in the 
liver from cholesterol and are important for the intestinal absorption of dietary lipids.1 The 
disposition of bile acids is tightly regulated because accumulation of these detergent-like 
molecules in hepatocytes can lead to cellular damage and cholestatic injury.2 Bile acids are 
secreted from the hepatocyte into the bile canaliculi by bile salt export pump (BSEP), an ATP 
binding cassette (ABC) transporter.3,4 The physiological importance of BSEP is demonstrated by 
inherited cholestatic conditions caused by genetic mutations in ABCB11, the gene encoding for 
BSEP. These conditions range in severity from those leading to progressive and persistent 
cholestasis requiring liver transplantation (as seen with progressive familial intrahepatic 
cholestasis (PFIC) Type II), to milder, self-limiting forms of cholestasis (reported in patients with 
benign recurrent intrahepatic cholestasis (BRIC)).5,6 Genetic variants in ABCB11 have been 
implicated as a potential contributing factor to the development of intrahepatic cholestasis of 
pregnancy (ICP). In ICP, pregnancy hormones precipitate the development of cholestasis, typically 
during the second trimester of pregnancy when estrogen levels are highest, consistent with the 
finding that these hormones alter bile acid disposition.7,8 In addition, the inhibition of BSEP by 
medications can lead to the accumulation of bile acids in the hepatocyte and contribute to the 
development of cholestatic drug-induced liver injury (DILI).9,10 
 DILI is a major, albeit rare, safety concern for both currently approved mediations and 
those in the drug development pipeline. DILI may lead to black-box warnings for currently used 
medications, and is the most common safety reason for the withdrawal of approved drugs from the 
market.11 Idiosyncratic DILI is difficult to predict during pre-clinical and early drug development, 
and accounts for 11% of all acute liver failure cases.12 Due to the extensive financial losses 
associated with the removal of an approved drug from the market, and the risk of severe clinical 
complications of DILI, early identification of compounds that are potentially hepatotoxic is 
imperative. However, this can be very challenging. In many cases, a liver toxicity signal is not 
observed in preclinical studies, and first appears during Phase III studies, or even after the drug is 
approved. Although BSEP inhibition is considered one of the contributing factors to the 
development of cholestatic DILI, even potent BSEP inhibitors cause hepatotoxicity in only a small 
subset of patients.9,13 For example, troglitazone, an antidiabetic medication withdrawn from the 
market due to DILI, and the metabolite, troglitazone sulfate, are both potent BSEP inhibitors.13,14 
However, even with potent in vitro BSEP inhibition, the incidence of patients presenting with 
elevated liver enzymes (ALT) during the clinical trials of troglitazone was only 1.9%.15 This 
indicates that there are additional factors that might increase a patient’s susceptibility to 
hepatotoxicity, and numerous candidate gene studies have been conducted to identify genetic 
factors that may contribute to the development of cholestatic DILI.   
A common variant in ABCB11, (rs2287622; c.1331T>C; p.V444A) has been reported to 
be associated with an increased risk of developing cholestatic DILI and ICP16, as well as with 
disease progression in hepatitis C.17,18 In a trial of patients presenting with cholestatic DILI, the 
CC genotype in ABCB11 was more common compared to patients without DILI.19 Similar 
associations between patients with the CC genotype  and the risk of contraceptive-induced 
cholestasis and ICP also have been reported.8,20 However, a similar study in a Japanese 
population found no association of cholestasis with this variant.21 Studies to explain the 
mechanistic basis for this increased susceptibility to acquired cholestatic syndromes have been 
unsuccessful. The expression of the variant BSEP is slightly lower in both liver tissue22 and in 
transfected systems.21,23,24 However, this variant is extremely common, with an allele frequency 
of 53% in African-Americans, 57% in European Americans,23 and 74% or higher in Mainland 
Chinese and other Asian populations.25,26 Thus, any clinically impactful changes in transporter 
expression of variant BSEP would place a large portion of the population at risk for DILI and 
ICP, which is not consistent with clinical observations.  
Functional studies have found that the kinetics of taurocholic acid (TCA) transport are 
similar between the reference and the variant forms of BSEP.19,23 TCA is a prototypical bile acid 
frequently used for in vitro studies because it is readily available radiolabeled. TCA is one of 
many bile acid species present in humans; each bile acid has a unique toxicity profile and 
substrate affinity for BSEP.27 In humans, glycine conjugated bile acids predominate over taurine 
conjugated bile acids.28 Interestingly, the transport kinetics of additional bile acid substrates such 
as glycocholic acid (GCA) have not been investigated for this variant. Furthermore, the 
inhibitory potential of medications for the reference and variant forms of BSEP warrants 
investigation. A previous study by Ulzurrun et al. evaluated the interaction between therapeutic 
class/chemical structure of a compound and the p.V444A variant in patients with DILI and found 
that for certain chemical moieties the association was stronger than others.29 However, this 
interaction between the BSEP variant protein and the inhibiting medication has not been 
experimentally verified. This study was designed to characterize the function of this common 
variant by determining the transport kinetics of GCA and evaluating the inhibitory potential of 




Spodoptera frugiperda 9 (Sf9) cells were obtained from the Tissue Culture Facility at the 
University of North Carolina-Chapel Hill. Cell culture media (Sf-900 II Serum Free Media) and 
TaqMan® genotyping supplies (including assay and master mix), were purchased from Thermo 
Fisher Scientific (Waltham, MA). BSEP antibody for immunoblot analysis was purchased from 
Abcam (ab140616; Cambridge, MA) and anti-rabbit IgG secondary antibody was purchased from 
Jackson ImmunoResearch (West Grove, PA). [14C]-Glycocholic acid (46.3 mCi/mmol; >97% 
radiochemical purity) and [3H]-taurocholic acid (9.74 Ci/mmol; >97% radiochemical purity) were 
purchased from Perkin Elmer (Waltham, MA). Compounds tested for inhibition studies were 
purchased from either Fisher Scientific (Thermo Fisher Scientific; Waltham, MA) or Sigma-
Aldrich (St. Louis, MO). The scintillation cocktail, Bio-Safe II Complete Counting Cocktail, was 
purchased from Research Products International (Mt. Prospect, IL). 
Generation and characterization of membrane vesicles:  
Baculoviral stocks for the expression of either the 444V (reference) or 444A (variant) 
BSEP were generated previously.19 The viral stocks were genotyped using TaqMan® Drug 
Metabolism Genotyping Assay (Catalog Number 4362691, Thermo Fisher Scientific). DNA was 
extracted from baculovirus stocks as described in the Easy-DNA™ Kit Manual (Catalog Number 
K1800-01, Life Technologies, Carlsbad, CA). The samples were genotyped for the rs2287622 
single nucleotide polymorphism (SNP) using a QuantStudio™ 6 Flex System (Applied 
BiosystemsTM Thermo Fisher Scientific) to confirm the genotype of the baculoviral stocks.   
Sf9 cells were infected with the baculoviral stocks and membrane vesicles were generated 
as described previously.19 Briefly, Sf9 cells were grown at 27 °C and were infected with either the 
444V or 444A baculovirus for an incubation period of 3 days. Following this incubation period, 
the cells were harvested and centrifuged to pellet the cells. The supernatant and the cell pellet were 
reconstituted in TMEP buffer (50 mM Tris, 50 mM Mannitol, 2 mM EGTA, adjusted to a pH of 
7.0 with HCl) containing protease inhibitors. The resulting suspension was homogenized using a 
glass-teflon homogenizer and centrifuged at 600 xg for 10 min. The supernatant was collected and 
centrifuged at 100,000 xg for 1 hr (Beckman Coulter 25,000 RPM). The resulting pellet was 
resuspended in SMS buffer (50 mM sucrose, 100 mM KNO3 and 10 mM Hepes, adjusted to pH 
7.4 using Tris) and the suspension was passed through a 27G needle to generate membrane 
vesicles. The protein concentration was determined using a BCA Protein Assay (Thermo Fisher 
Scientific) and vesicles were aliquoted and stored at -80 °C. The protein expression of BSEP in 
the reference and variant vesicles was measured using immunoblot analysis as previously 
described.30  
Transport of TCA was measured to characterize the functionality of the generated 
membrane vesicles using the assay conditions described previously.31 The kinetics of GCA 
transport mediated by reference and variant BSEP were evaluated by incubating membrane 
vesicles (10 µg/reaction) for 1 min with approximately 2 µM of [14C]-GCA along with unlabeled 
GCA over a range of concentrations (1, 10, 25, 50, 100 µM) in the presence or absence of 4 mM 
ATP. The reaction was stopped by addition of ice-cold buffer, and the samples were filtered 
through glass fiber filters that were pre-soaked in a solution of unlabeled GCA (1 mM). The filters 
were dissolved in scintillation cocktail and the amount of radioactivity in the vesicles was 
measured by scintillation counting. Radioactivity in the vesicles incubated without ATP was 
subtracted from radioactivity in the vesicles incubated with ATP to determine ATP-dependent 
transport. Nonlinear regression analysis was used to estimate the Vmax and Km values using 
GraphPad Prism version 7.04 (La Jolla, California). 
Inhibition Studies: 
Previous studies reported a possible association between the pharmacological drug 
class/chemical moieties and susceptibility to cholestasis in patients expressing the variant 
protein.29 A panel of these compounds was tested as inhibitors of both TCA (2 µM; incubation 
time of 2 min) and GCA transport (10 µM; incubation time of 1 min) mediated by reference and 
variant BSEP to identify any substrate specific differences in inhibitory potential. Inhibition 
studies were conducted at an inhibitor concentration of 100 µM. Transport activity in the presence 
of inhibitors was normalized to transport activity measured in the control (DMSO) group for both 
the reference and variant BSEP to obtain the relative activity (% Activity).  
Additional inhibition studies were conducted to further characterize interactions between 
DILI associated compounds and the V444A variant. TCA was used as the substrate in these studies 
because it is the prototypical BSEP substrate, and has been used in previous studies to identify 
inhibitors.10,32 Compounds tested as inhibitors included causative cholestatic DILI medications as 
identified through the Drug-Induced Liver Injury Network (DILIN) registry, a prospective registry 
of patients with DILI established by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK).33 Compounds that had been tested in the inhibition study with TCA and GCA 
were excluded from this analysis (amoxicillin-clavulanate, dipyridamole, isoniazid, regorafenib). 
Forty-six compounds associated with cholestatic DILI were tested as TCA inhibitors. Test 
compounds were dissolved in DMSO and inhibition studies were conducted at a concentration of 
100 µM in a high-throughput assay, as described previously.34 Compounds that had a fold-change 
of <0.5 or >2 between the reference and variant protein were selected for further investigations to 
determine IC50 values. All inhibition studies were conducted in triplicate; the experiments using 
TCA as a substrate were conducted in one experiment. Inhibition studies that utilized GCA as a 
substrate were conducted in two independent experiments (n=2) because the inhibition of BSEP-
mediated GCA transport by these compounds had not been reported previously.  
Statistical analysis: 
An extra sum-of-squares F test was used to compare independent fits that described the 
kinetics of GCA transport for the reference and variant forms of BSEP to a global fit curve that 
described both sets of observations. Statistically significant differences between reference and 
variant BSEP in the transport of TCA or GCA were tested using a two-way ANOVA with a Sidak 
test to correct for multiple-comparisons. 
  
Results:  
Expression of both reference and variant BSEP in Sf9 derived membrane vesicles 
determined by western blot analysis were similar (Figure 1). TCA transport for both reference and 
variant forms of BSEP was comparable(Supplementary Figure 1). The transport kinetics of GCA 
for reference and variant BSEP followed Michaelis-Menten kinetics with Vmax values of 1132 ± 
246 vs. 959 ± 256 pmol/min/mg protein, respectively, and Km values of 32.74 ± 18.25 vs. 45.70 ± 
25.52 µM, respectively. GCA transport was not significantly different between reference and 
variant BSEP (p=0.0784) over the range of concentrations studied.  
  Under all conditions tested,  BSEP was inhibited strongly (defined here as greater than 
75% inhibition) by dipyridamole, erythromycin, and ketoconazole (Figure 2 and Supplementary 
Table 1).  A slight potentiation of reference and variant BSEP-mediated TCA and GCA transport 
was observed with amoxicillin-clavulanate. There were no statistically significant differences in 
% Activity in the presence of the compounds tested for either substrate (TCA or GCA) between 
reference and variant BSEP.  
Of the DILIN compounds tested in the TCA inhibition study, ten compounds exhibited a 
greater than 50% reduction in TCA transport by reference BSEP (Figure 3). These compounds 
included amiodarone, torimefene, the clinically used combination of norgestimate and ethinyl 
estradiol, chlorothiazide, cefazolin, allopurinol, and acyclovir.  The mean % Activity of reference 
and variant BSEP in the presence of the tested inhibitors (100 µM) was within a 2-fold difference, 
except for sulindac (Figure 3 and Supplementary Table 2). However, when sulindac was tested 
over a range of concentrations (up to 200 µM), the IC50 values were similar between the reference 
(109.3±25.4 µM) and variant (136.2±25.1 µM) BSEP. 
Discussion 
 The functional impact of V444A, a common variant in BSEP, was evaluated in this study 
to identify a mechanistic explanation for the reported association of this SNP with acquired 
cholestasis. Potential changes in the substrate affinity were first examined by measuring the 
transport kinetics of GCA. Then, the inhibition of reference and variant BSEP by cholestatic 
compounds was investigated to test whether the two forms of the protein differ in their 
susceptibility to drug inhibition, thereby providing functional data supporting the association with 
DILI. 
Variant (444A) BSEP has been reported to be associated with an increased risk of both 
cholestatic DILI and ICP in multiple studies. In a candidate gene study of patients with DILI, the 
CC genotype (444A) in ABCB11 was more common in patients with DILI than in the control 
group.19 Similar findings also were reported in European and Caucasian populations,29 however, 
no statistically significant association was reported in studies conducted in Chinese and Japanese 
cohorts.21,35 The 444A variant of BSEP also has been identified as a risk factor for the development 
of ICP, with the variant being more frequent in ICP patients when compared to pregnant 
controls.8,20,36 Dixon et al. reported an increased risk of ICP in subjects with the 444A variant, 
especially those who were homozygous for this BSEP variant. However, structural analysis 
utilizing homology modeling with the bacterial transporter protein Sav1866 found no molecular 
basis for the association reported with the V444A variant.8 Based on in silico tools that are used 
to predict the functional consequences of SNPs, the V444A variant is predicted to be benign.25  
These predictions are in line with in vitro results demonstrating that the transport of TCA 
by reference and variant BSEP are identical.19,23 However, other bile acids, including GCA, are 
also transported by BSEP and exhibit different transport kinetics.3,4,27 In the present study, the 
transport of GCA was evaluated to test the hypothesis that this bile acid, which is one of the 
predominant bile acids present in humans28 with lower affinity for BSEP,27,37 exhibits substrate 
specific differences due to the SNP. The transport kinetics of GCA over the range of concentrations 
studied was not statistically different between reference and variant BSEP, indicating that there 
are no significant changes in GCA transport due to this variant. The Km estimates in the present 
study are similar to those previously reported for reference BSEP-expressing membrane vesicles. 
38,39 It was demonstrated previously that there was no difference in the transport kinetics of TCA 
between the two variants.19 This kinetic similarity is not surprising, since amino acid p.444 is 
located in the large cytoplasmic domain of BSEP linking the two transmembrane domains.19 
The p.444A variant of BSEP is associated with acquired cholestatic DILI and ICP, 
conditions where cholestasis is precipitated either due to a medication or an endogenous hormone. 
Therefore, it is essential to identify any potentially different drug-transporter interactions between 
reference and variant BSEP. Compounds tested in the first set were those that had been reported 
previously to have statistical associations with variant BSEP.29 The inhibition of both TCA and 
GCA transport was tested to screen for any potential substrate-  and/or variant-specific drug 
inhibition. The results from the inhibition screening using TCA as the substrate were in agreement 
with previously published IC50 values for reference BSEP.13 For example, compounds that strongly 
inhibited BSEP activity in our study (dipyridamole, erythromycin, ketoconazole) were reported to 
be potent inhibitors.13 Additionally, compounds that did not inhibit BSEP activity in our study 
(including isoniazid, ketorolac, levofloxacin) also have been classified as non-inhibitors.13 For the 
tested compounds, no differences in the inhibition of TCA or GCA were observed between 
reference and variant BSEP. A similar interaction of the inhibitors with TCA and GCA was likely 
because substrate concentrations well below the respective Km values were used.38,39 Follow-up 
inhibition studies utilized TCA as the substrate and tested cholestatic compounds from the DILIN 
registry using a high-throughput method. Although inhibition of sulindac was statistically different 
in the high-throughput screen, when sulindac was tested over a range of concentrations, the IC50 
values were similar for both reference and variant BSEP. The results from the inhibition studies 
conducted here do not demonstrate any variant specific drug interactions with BSEP that would 
explain the association with DILI.  
 Although a thorough characterization of the functional activity of this common BSEP 
variant was conducted, there are a few limitations that should be acknowledged. Membrane 
vesicles expressing the transporter of interest are an important in vitro tool to characterize 
transporter function, but they do not reflect the complex and dynamic processes that regulate BSEP 
expression and function in hepatocytes.19 Membrane vesicles lack the machinery to allow the study 
of localization and trafficking, which could be altered in this particular BSEP variant. Although 
this study utilized TCA and GCA as substrates, potential variant-specific functional changes in the 
transport kinetics of more toxic bile acids cannot be ruled out. However, such changes are unlikely 
due to the location of the variant amino acid in the protein, as discussed above, and the comparable 
affinities between reference and variant BSEP for most bile salts tested so far.39 Additionally, there 
could be other rare variants in ABCB11 that alter function and localization and are yet to be 
identified. The low frequency of DILI and ICP, and the high frequency of the variant BSEP (50-
70% depending on the ethnic population), are consistent with our findings that this variant does 
not have major alterations in BSEP function.  
In this functional evaluation of the common V444A variant of BSEP, no differences in the 
transport of the bile acid substrate GCA were observed compared with reference BSEP. 
Additionally, no substrate- or genotype-specific differences were observed in the inhibition 
potential of medications associated with cholestatic DILI. Under the conditions tested in these 
studies, no significant functional differences between variant and reference BSEP were identified 
that would explain the association of this variant with DILI and ICP.  
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Figure 1: Comparison of GCA transport kinetics mediated by reference and variant BSEP. [A] BSEP 
levels were similar in reference and variant membrane vesicles based on western blot analysis. [B] 
Membrane vesicles were incubated with a range of GCA concentrations in the presence or absence of 4 mM 
ATP for 1 min. The difference in curves for ATP-dependent transport of GCA by the reference and variant 





Figure 2: Inhibition of TCA and GCA transport mediated by reference and variant BSEP. Mean 
values (% Activity based on the color-coded bar on the right where 100% indicates no inhibition and 0% 
indicates complete inhibition) were normalized to DMSO (Mean±SD values from n=1-2 experiments 
conducted in triplicate). 
 
 
Figure 3: Inhibition of TCA transport mediated by reference and variant BSEP. Compounds from the 
DILIN Registry were tested at a concentration of 100 μM. Data are expressed as % Activity normalized to 
DMSO, where 100% indicates no inhibition. (Mean ± SD from n=1 experiment conducted in triplicate). 
